What is the global market size of Idiopathic Pulmonary Fibrosis Market?

Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.31 billion in 2021 and is poised to grow from USD 3.54 billion in 2022 to USD 6.04 billion by 2030, at a CAGR of 6.9% during the forecast period (2023-2030).

Who are the key vendors in the Global Idiopathic Pulmonary Fibrosis Market?

The competitive landscape of the Global Idiopathic Pulmonary Fibrosis (IPF) Market is characterized by intense research and development activities focused on developing innovative treatment options and improving patient outcomes. Pharmaceutical companies are actively engaged in introducing antifibrotic agents and targeted therapies to address the unmet medical needs of IPF patients. Additionally, healthcare providers and research institutions play a crucial role in advancing diagnostic techniques and patient care, while advocacy groups and patient organizations contribute to raising awareness about IPF and its management. The market's competitiveness is further driven by regulatory approvals, market penetration strategies, and efforts to enhance healthcare infrastructure and access to IPF treatments globally. 'Cipla Inc. (India)', 'Boehringer Ingelheim International GmbH (Germany)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'FibroGen, Inc. (US)', 'Horizon Therapeutics plc (Ireland)', 'AstraZeneca (UK)', 'Novartis AG (Switzerland)', 'GlaxoSmithKline plc (UK)', 'Genentech, Inc. (US)', 'Bristol Myers Squibb (US)', 'Biogen Inc. (US)', 'Actelion Pharmaceuticals Ltd. (Switzerland)', 'Pfizer Inc. (US)', 'Johnson & Johnson (US)', 'Sanofi (France)', 'Merck & Co., Inc. (US)', 'Gilead Sciences, Inc. (US)', 'AbbVie Inc. (US)', 'Bayer AG (Germany)', 'Amgen Inc. (US)'

What is the key driver of Global Idiopathic Pulmonary Fibrosis Market?

A key driver of the Global Idiopathic Pulmonary Fibrosis (IPF) Market is the continuous advancement in medical research and drug development. The ongoing efforts to understand the underlying mechanisms of IPF and develop innovative therapies have resulted in the introduction of new treatment options, such as antifibrotic agents like Nintedanib and Pirfenidone. These advancements have significantly improved patient outcomes and quality of life, driving the growth of the market.

What is the key market trend for Global Idiopathic Pulmonary Fibrosis Market?

Increasing focus on the development of targeted therapies: One key market trend in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the increasing focus on the development of targeted therapies. Pharmaceutical companies and researchers are actively exploring and investing in innovative treatment approaches that specifically target the underlying mechanisms and pathways responsible for IPF. This trend aims to offer more effective and personalized treatment options, potentially leading to improved patient outcomes and better disease management. Targeted therapies hold promise in addressing the complex nature of IPF and may pave the way for more tailored and precise treatments in the future.

Which region accounted for the largest share in Global Idiopathic Pulmonary Fibrosis Market?

North America dominated the Global Idiopathic Pulmonary Fibrosis (IPF) Market. The region's leading position can be attributed to well-established healthcare infrastructure, high awareness about IPF among healthcare professionals and patients, and a strong focus on research and development. North America is home to several key pharmaceutical companies actively involved in developing and marketing IPF therapies. Additionally, favorable reimbursement policies and early adoption of novel treatments contribute to the region's dominance in the IPF market.

Idiopathic Pulmonary Fibrosis Market Size, Share, Growth Analysis, By Drug Type(Nintedanib, Pirfenidone, Other Drug Types), By Mode of Action(Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By End User(Hospitals and Clinics, Pharmacies, Other End Users ), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2223 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 61 | Figures: 75

Idiopathic Pulmonary Fibrosis Market News

Plans to file a new drug application for the treatment of IPF were prompted by an announcement that Boehringer Ingelheim issued on September 2024 stating that nerandomilast FIBRONEER-IPF trial achieved its primary objective.
Options for Indications of Idiopathic and Progressive Pulmonary Fibrosis, Ferrer extended the exclusive licensing agreement in May 2024 with United Therapeutics to acquire worldwide rights of treprostinil inhalation solution.
Daewoong Pharmaceutical and CS Pharmaceuticals agreed on the license for the first-in-class PRS inhibitor Bersiporocin to be distributed in Greater China in January 2023. It involves mainland China, Hong Kong, Taiwan, and Macau. For the aggregate amount up to USD 336m consisting of the sum of up to USD 76m in milestone payments due upon the achievement of specified development milestones, plus double-digit royalties on net sales, CSP shall license in bersiporocin for IPF and for other fibrotic conditions.

Idiopathic Pulmonary Fibrosis Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.50 billion in 2022 and is poised to grow from USD 4.02 billion in 2023 to USD 10.80 billion by 2031, growing at a CAGR of 6.98% during the forecast period (2024-2031).

The competitive landscape of the global idiopathic pulmonary fibrosis (IPF) industry is characterized by intensive research and development work on developing new treatment modalities and improving patient outcomes. Pharmaceutical companies are aggressively launching targeted treatments and antifibrotic medicines to fulfill the unmet medical needs of IPF patients. Patient organizations and advocacy groups are also assisting in raising awareness about IPF and its treatment; however, healthcare professionals and research institutions play a critical role in improving patient care and diagnostic approaches. 'United Therapeutics Corporation ', 'Boehringer Ingelheim International GmbH ', 'Bristol-Myers Squibb Company ', 'Cipla Inc. ', 'F. Hoffmann-La Roche Ltd ', 'FibroGen Inc. ', 'MediciNova Inc. ', 'Jubilant Pharma Limited (Jubilant Cadista Limited) ', 'Merck & Co. Inc. ', 'Horizon Therapeutics Inc. ', 'Avalyn Pharma Inc. ', 'AstraZeneca ', 'Novartis AG ', 'GlaxoSmithKline plc ', 'Genentech, Inc. ', 'Biogen Inc. ', 'Pfizer Inc. ', 'AbbVie Inc. ', 'Bayer AG ', 'Amgen Inc.'

The prevalence of idiopathic pulmonary fibrosis is rising due to the growing age of the population and increasing environmental factors that include and more than which is air pollution and occupational exposures. Such increased awareness among patients and medical professionals also contributes to this increasing incidence that leads to increased diagnosis. The growing demand for advanced treatment and management options is an important factor driving the idiopathic pulmonary fibrosis market growth.

Trend of Personalized Medication: One of the major idiopathic pulmonary fibrosis market trends includes personalization of medicines. Personalized medication in idiopathic pulmonary fibrosis IPF is growing rapidly in the market. Advances in the genetics field and discovery of biomarkers have made possible individualized treatment plans, introduced by healthcare experts for the first time. Tailor-made medicines for the characteristics of each patient will continue to increase the effectiveness of therapy, which will bring improvements in disease management as well as treatment and overall outcomes for patients.

As per the idiopathic pulmonary fibrosis market forecast, North America dominated the market with 37.5% revenues in 2024. Developed healthcare infrastructure, well-equipped hospitals, and specialist IPF diagnostic and management skills facilitate timely and efficient treatment in the region. In addition, access to authorized treatments such as pirfenidone and nintedanib is supplemented by strong R&D with favorable reimbursement policies. The U.S. market captured the largest share of the North America market for the treatment of idiopathic pulmonary fibrosis in 2024. The nation is well-supported by a developed health care system, which permits timely diagnosis and effective decision of the treatment. The fast approval of medicines pirfenidone and nintedanib improved access for patients, while continued research and development activities in the United States continue to foster innovative therapeutic approaches.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Idiopathic Pulmonary Fibrosis Market News

Idiopathic Pulmonary Fibrosis Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Idiopathic Pulmonary Fibrosis Market?

Who are the key vendors in the Idiopathic Pulmonary Fibrosis Market?

What is the key driver of Idiopathic Pulmonary Fibrosis Market?

What is the key market trend for Idiopathic Pulmonary Fibrosis Market?

Which region accounted for the largest share in Idiopathic Pulmonary Fibrosis Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300